<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leniolisib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leniolisib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Leniolisib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="141134" href="/d/html/141134.html" rel="external">see "Leniolisib: Drug information"</a> and <a class="drug drug_patient" data-topicid="141168" href="/d/html/141168.html" rel="external">see "Leniolisib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58009285"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Joenja</li></ul></div>
<div class="block dop drugH1Div" id="F58006040"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5109ca07-b04b-4a00-9d1e-4ce2389791a0">Activated phosphoinositide 3-kinase delta syndrome, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome, treatment:</b> Children ≥12 years and Adolescents, weighing ≥45 kg: Oral: 70 mg every 12 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F58006092"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58006093"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents, weighing ≥45 kg: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied. Leniolisib is metabolized extensively (60%) by the liver; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Use not recommended; has not been studied.</p></div>
<div class="block doa drugH1Div" id="F58045021"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="141134" href="/d/html/141134.html" rel="external">see "Leniolisib: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4e96ea8-90a6-42a7-a728-012388f5e706">Activated phosphoinositide 3-kinase delta syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Activated phosphoinositide 3-kinase delta syndrome: Oral:</b> Weight ≥45 kg: 70 mg twice daily, approximately every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36399712','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36399712','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose</i>
<i>:</i> If a dose is missed by &gt;6 hours, skip the missed dose and administer the next dose at the usual time. If a dose is vomited ≤1 hour after administration, administer another dose as soon as possible; if vomited &gt;1 hour after administration, do not readminister the dose (administer the next dose at the usual time).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58045023"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F58045024"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B or C): Use is not recommended (effect on leniolisib pharmacokinetics has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F58652206"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Neutropenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia</b> has been reported with leniolisib. In a clinical study, this absolute neutrophil count (ANC) decrease did not result in infections and was considered mild and transient. No ANC &lt;500 cells/µL or events ≥ grade 3 were reported (Rao 2023<span style="text-decoration: underline">)</span>.</p>
<p style="text-indent:-2em;margin-left:2em;">Transient and mild <b>neutropenia</b> has been reported with leniolisib. In clinical studies, an absolute neutrophil count (ANC) &lt;500 cells/µL, events ≥ grade 3, and infection were not reported (Rao 2023<span style="text-decoration: underline">)</span>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; nadir at day 15 with recovery by day 85 has been reported (Rao 2023).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F58001504"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Atopic dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F58001258"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58044843"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Live attenuated vaccinations may be less effective when administered during leniolisib treatment.</p></div>
<div class="block foc drugH1Div" id="F58009286"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as phosphate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Joenja: 70 mg</p></div>
<div class="block geq drugH1Div" id="F58009284"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58081570"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Joenja Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $944.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F58006094"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. If patient vomits ≤1 hour after dose, readminister dose as soon as possible; if patient vomits &gt;1 hour after dose, do not readminister dose; wait and administer next dose at scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;">Missed dose: If dose missed by &gt;6 hours, wait and take next dose at scheduled time.</p></div>
<div class="block adm drugH1Div" id="F58045025"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer doses approximately every 12 hours, with or without food. If vomiting occurs ≤1 hour after administration, administer another dose as soon as possible. If vomiting occurs &gt;1 hour after administration, do not readminister the dose; wait and administer the next dose at the usual time.</p></div>
<div class="block sts drugH1Div" id="F58044849"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F); do not refrigerate. Store and dispense in original container.</p></div>
<div class="block usep drugH1Div" id="F58001431"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F58044839"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Joenja may be confused with Jolessa, Jorveza.</p>
<p style="text-indent:0em;margin-left:2em;">Leniolisib may be confused with alpelisib, copanlisib, duvelisib, idelalisib, lenvatinib.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58037951"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F58037948"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Leniolisib may increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Leniolisib may increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Leniolisib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Leniolisib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Leniolisib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Leniolisib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors): Leniolisib may increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Leniolisib may diminish the therapeutic effect of Vaccines (Live). <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58044840"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use; verify the patient is not pregnant prior to treatment initiation (in patients who could become pregnant).</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use highly effective contraception during therapy and for 1 week after the last leniolisib dose.</p></div>
<div class="block pri drugH1Div" id="F58044841"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on data from animal reproduction studies, in utero exposure to leniolisib may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F58006095"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pregnancy test in patients who can become pregnant (prior to the initiation of therapy and as deemed clinically necessary during treatment and up to 1 week after stopping therapy); liver function tests; complete blood count with differential.</p></div>
<div class="block pha drugH1Div" id="F58044850"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Leniolisib is a kinase inhibitor that selectively targets phosphoinositide 3-kinase (PI3K) delta (Rao 2023). Leniolisib blocks the active binding site of PI3K delta, inhibiting the signaling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and dysregulation of B and T cells.</p></div>
<div class="block phk drugH1Div" id="F58044851"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~28.5 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94.5%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4, with minor contribution to metabolism by CYP3A5, CYP1A2, and CYP2D6.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: ~10 hours; Effective: ~7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Median: ~3 hours (range: 1 to 5 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Median: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 25.5% (6.32% as unchanged drug); feces: 67%.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Joenja.1">
<a name="Joenja.1"></a>Joenja (leniolisib) [prescribing information]. Fallavier, France: Skyepharma Production; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36399712">
<a name="36399712"></a>Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. <i>Blood</i>. 2023;141(9):971-983. doi:10.1182/blood.2022018546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leniolisib-pediatric-drug-information/abstract-text/36399712/pubmed" id="36399712" target="_blank">36399712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li></ol></div><div id="topicVersionRevision">Topic 141135 Version 14.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
